Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nebivolol hydrochloride
Drug ID BADD_D01542
Description Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity.[A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol].[A182579] Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics.[A182594] Nebivolol was granted FDA approval on 17 December 2007.[L7985]
Indications and Usage Nebivolol is indicated to treat hypertension.[A2762,A182579,L7985,L7988]
Marketing Status approved; investigational
ATC Code C07AB12
DrugBank ID DB04861
KEGG ID D06622
MeSH ID D000068577
PubChem ID 9933004
TTD Drug ID D0Z1UA
NDC Product Code 29300-377; 0456-1402; 0456-1420; 0456-1411; 0456-1421; 50370-0012; 66577-024; 29300-378; 50090-1127; 50090-3326; 65691-0062; 69037-0004; 76397-009; 0456-1410; 64220-187; 76397-008; 29300-375; 29300-376; 68462-617; 0456-1403; 0456-1406; 52133-0039; 50090-1307; 68462-618; 68462-615; 68462-616; 0456-1405
UNII JGS34J7L9I
Synonyms Nebivolol | Alpha,Alpha'-(Iminobis(Methylene))bis(6-Fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol | Bystolic | Nebilet | Silostar | Nebivolol Hydrochloride | Hydrochloride, Nebivolol | R 67555 | 67555, R | R-67555 | R67555 | Lobivon
Chemical Information
Molecular Formula C22H26ClF2NO4
CAS Registry Number 152520-56-4
SMILES C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Acute pulmonary oedema22.01.03.005; 02.05.02.004--Not Available
Alanine aminotransferase increased13.03.04.005--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Atrioventricular block02.03.01.002--Not Available
Blood bilirubin increased13.03.04.018--
Blood triglycerides increased13.12.03.001--Not Available
Blood urea increased13.13.01.006--Not Available
Blood uric acid increased13.02.04.001--Not Available
Bradycardia02.03.02.002--Not Available
Bronchospasm10.01.03.012; 22.03.01.004--
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dyspnoea02.11.05.003; 22.02.01.004--
Fatigue08.01.01.002--
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
High density lipoprotein decreased13.12.01.003--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hypersensitivity10.01.03.003--
Hypersensitivity vasculitis24.12.04.013; 23.06.02.005; 10.02.02.017; 01.01.04.008--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intermittent claudication24.04.03.001--Not Available
Myocardial infarction02.02.02.007; 24.04.04.009--
Nausea07.01.07.001--
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Paraesthesia23.03.03.094; 17.02.06.005--
The 1th Page    1 2    Next   Last    Total 2 Pages